glp 1 stock market GLP-1 Drugs Drop More Than Just Weight GLP-1 Receptor Agonist Market Size

Pooled data from seven randomized controlled trials involving 680 adult participants demonstrated meaningful weight-loss outcomes, with non-diabetic individuals achieving reductions of up to 8.44% and diabetic participants achieving approximately 3.55% weight loss over a 24-week periods

Dose titration strategies represent an important consideration

Standing desks, walking meetings, household activity, and general restlessness are all forms of NEAT that support weight maintenance

GLP-1 agonists should also be avoided by those with a history of thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN 2), as these conditions may increase the risk of medullary thyroid carcinoma